Is Ambey Laborator. overvalued or undervalued?

As of 16 September 2025, the valuation grade for Ambey Laborator. has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios include a PE Ratio of 21.40, an EV to EBIT of 21.19, and a Price to Book Value of 1.34, which suggest that the stock is trading at a premium compared to its earnings and book value.
In comparison to its peers, Ambey Laborator. has a lower PE Ratio than P I Industries, which stands at 35.02, and Bayer CropScience at 39.94, both of which are also categorized as very expensive. However, it is notably higher than UPL, which is rated as attractive with a PE Ratio of 35.19. The company's recent stock performance has been underwhelming, with a year-to-date return of -32.94%, contrasting sharply with the Sensex's gain of 6.74% in the same period, reinforcing the notion of overvaluation.